Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and
PK of OMP-54F28 when combined with sorafenib. OMP-54F28 will be administered IV on Day 1 of
each 21-day cycle. The planned dose levels of OMP-54F28 are 5 and 10 mg/kg. Depending on
safety in this study, additional lower or intermediate dose levels may be evaluated.